ENTITY

Silence Therapeutics (SLN LN)

Analysis

Health Care • United Kingdom

Silence Therapeutics plc, a RNA technology company, engages in the development and delivery of RNA therapeutics. The company has an intellectual property portfolio, encompassing proprietary and in-licensed patents and patent applications, covering various aspects of its RNA based therapeutics. Its patented RNA interference (RNAi) platform, AtuRNAi, is based on specific proprietary short interfering RNA (siRNA) modules, stabilization technology, and other features. The company also has proprietary lipid based RNA delivery technology platforms that comprise AtuPLEX, a lipid based siRNA formulation that delivers RNAi to the vascular endothelium; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and HepaPLEX formulation that delivers siRNA primarily to the liver. It is developing Atu027, an RNAi drug candidate that has completed a Phase IIa study in pancreatic cancer. The company?s pre-clinical programs include Atu111 for the treatment of lung diseases; Messenger RNA (mRNA) delivery, a method of introducing messenger RNA activity into the cell, in conditions where this is of therapeutic interest; and MicroRNA delivery that mediate natural cellular mechanisms, which exist to regulate gene expression. It is also developing GalNAc conjugated siRNA for liver delivery and products for pulmonary arterial hypertension. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Refresh

Focused

bullish•Hansoh Pharmaceutical Group

•09 Apr 2022 21:45

Hansoh Pharmaceutical (3692 HK): Bottom-Fishing Idea; Market Is Overlooking Innovative Portfolio

Hansoh has now six innovative drugs in its portfolio. With 40%+ revenue coming from new drugs, Hansoh has best-in-class margin profile. Rich...

Tina Banerjee

616 Views

bearish•Thematic (Sector/Industry)

•18 Oct 2021 08:51

China Healthcare Weekly (Oct15)-Growth Hormone VBP, Biotech's Business Model,Innovative Drug Outlook

The article analyzed the VBP on recombinant human growth hormone, the difference in business model of big pharma/biopharma and biotech, and the...

Xinyao (Criss) Wang

213 Views

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00